Screening of PotentialAntiviral Compounds - Assessing Efficacies Against Dengue Virus
Date
2024-03
Authors
Olanrewaju, Adeyemi A.
Esan, Taiwo
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Epidemiology
Dengue viruses (DENV) are spread to people through the bite of an infected Aedes species (Ae. Aegypti or Ae. albopictus)mosquito. Approximately, more than 3 billion people live in areas with high risk of dengue. It is the leading cause of illness in areas with risk vector borne disease (CDC, 2023).
Genome
DENV is a member of the Flavivirus genus of single-stranded positive-sense RNA viruses that causes severe generalized diseases in humans. There are four DENV serotypes (1, 2, 3 and 4), with type 2 and 3 being the most virulent forms (Vicente et al. 2016).
Structure
Mature DENV particles have a diameter of approximately 500nm. The surface is made up of a lipid bilayer which incorporate two transmembrane viral proteins to form a glycoprotein shell. The core contains the nucleocapsid formed by a viral RNA genome complex with capsid protein. The glycoprotein shell has 180 copies of envelope (E) and membrane protein (M or prM). The capsid (C) protein interacts with the viral RNA genome during assembly of the virus (Murugesan and Manoharan 2019).
Description
Keywords
antiviral, dengue virus
Citation
Olanrewaju, A., & Esan, T. (2024). Screening of potential antiviral compounds - Assessing efficacies against dengue virus. Poster presented at the Health Scholar Showcase, Translational Health Research Center, San Marcos, Texas.